Health care stocks declined Thursday afternoon with the NYSE Health Care Index shedding 0.7% and the Health Care Select Sector SPDR Fund (XLV) falling 1.2%.
The iShares Biotechnology ETF (IBB) dropped 1%.
In corporate news, Novo Nordisk (NVO) Chief Executive Officer Lars Fruergaard Jorgensen said the company will feel the impact of President Donald Trump's threatened tariffs despite its investments in the US, according to media reports. Novo shares declined 3.4%.
Plus Therapeutics (PSTV) shares surged 98% after it said Thursday that its Rhenium obisbemeda radiotherapy has been granted orphan drug designation by the US Food and Drug Administration for treating leptomeningeal metastases in lung cancer patients.
BridgeBio Pharma (BBIO) shares were falling past 6% after KKR Genetic Disorder disclosed the sale of 6 million BridgeBio shares in a regulatory filing.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.